13.73
-0.54(-3.78%)
Currency In USD
| Previous Close | 14.27 |
| Open | 14.24 |
| Day High | 14.65 |
| Day Low | 13.45 |
| 52-Week High | 15.74 |
| 52-Week Low | 2.69 |
| Volume | 24,685 |
| Average Volume | 40,733 |
| Market Cap | 36.79M |
| PE | -0.58 |
| EPS | -23.81 |
| Moving Average 50 Days | 12.23 |
| Moving Average 200 Days | 8.06 |
| Change | -0.54 |
If you invested $1000 in NextCure, Inc. (NXTC) since IPO date, it would be worth $57.5 as of February 21, 2026 at a share price of $13.73. Whereas If you bought $1000 worth of NextCure, Inc. (NXTC) shares 5 years ago, it would be worth $92.57 as of February 21, 2026 at a share price of $13.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NextCure Provides Business Update
GlobeNewswire Inc.
Jan 23, 2026 12:00 PM GMT
SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-s
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 20, 2025 1:00 PM GMT
BELTSVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
Extends cash runway into first half of 2027, beyond planned first half of 2026 proof of concept (“POC”) data readouts of SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC)Led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, and Exome